XMP: Phase I data

In a 3-week Phase I trial in 35 healthy adults, XMP.629 was well tolerated. Subjects received vehicle gel, 0.1% XMP.629 gel and 0.3% sodium lauryl sulfate as a positive control via separate occlusive ...